The benefits and risks of maternal RSV vaccination on mortality in South Africa: A modeling study.

ABSTRACT:

Background

Maternal respiratory syncytial virus (RSV) vaccine, RSV prefusion F protein vaccine (RSVpreF (Abrysvo)), was found to be safe and efficacious in the MATISSE trial. However, post-hoc stratified analyses identified an excess of preterm births in the intervention arm in two upper-middle-income countries, most prominently in South Africa. This study weighs the potential benefits and risks in mortality associated with maternal RSV vaccination in South Africa, assuming the increased risk of preterm births observed in the trial was caused by vaccination.

Methods and findings

We compared the estimated RSV-associated infant deaths averted by vaccination (benefits) and neonatal mortality potentially associated with vaccine-associated risk in preterm birth (risks) in South A

SUBMITTER: Monoi A 

PROVIDER: S-EPMC12818683 | biostudies-literature | 2026 Jan

REPOSITORIES: biostudies-literature